Ironwood Pharmaceuticals (IRWD) Gains from Investment Securities (2015 - 2023)

Ironwood Pharmaceuticals has reported Gains from Investment Securities for 9 years, with the latest figure at -$19000.0 in Q1 2023.

• Quarterly Gains from Investment Securities rose 95.44% year-over-year to -$19000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was -$19000.0 (up 89.56% YoY) and the FY2023 annual result came in at -$19000.0, up 89.56% from the prior year.
• Gains from Investment Securities eased to -$19000.0 in Q1 2023 per IRWD's latest filing, from $1.1 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $15.5 million in Q4 2019 and troughed at -$15.7 million in Q3 2019.
• A 5-year average of -$406647.1 and a median of -$151000.0 in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2019 and 2020: Gains from Investment Securities soared 998.63% in 2019, then plunged 314.28% in 2020.
• Over 5 years, Gains from Investment Securities stood at $15.5 million in 2019, then plunged by 71.64% to $4.4 million in 2020, then sank by 194.99% to -$4.2 million in 2021, then surged by 127.15% to $1.1 million in 2022, then tumbled by 101.68% to -$19000.0 in 2023.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$19000.0, $1.1 million, and -$151000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.